For citations:
Avxentyev N.A., Makarov A.S., Frolov M.Yu. Direct medical costs of using enzalutamide or abiraterone in chemotherapy-naïve patients with metastatic castration resistant prostate cancer. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2018;11(4):16-27. (In Russ.) https://doi.org/10.17749/2070-4909.2018.11.4.016-027

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.